Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ayvaco
Philadelphia, Pennsylvania, USAayvaco.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ayvaco is a biotechnology company specializing in the development of synthetic DNA vaccines and immunotherapies for infectious diseases and cancer. Spun out from The Wistar Institute, the company utilizes a proprietary platform to create DNA-based candidates that are thermally stable and capable of inducing potent immune responses. Ayvaco's lead program, AV-001, is a vaccine candidate targeting COVID-19, designed to provide broad protection against variants. The company's leadership includes world-renowned experts in DNA vaccinology and immunology. Ayvaco aims to streamline vaccine production and distribution to improve global access to life-saving preventatives.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- DNA vaccineSynthetic oligonucleotideImmunotherapy
- Industry
- Biotech
02
Partnerships
The Wistar Institute
Beyond the preview
Go deeper on Ayvaco.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ayvaco.